Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamotrigine clinical pharmacokinetics

B Rambeck1, P Wolf

  • 1Epilepsy-Centre Bethel, Gesellschaft für Epilepsieforschung, Bielefeld, Federal Republic of Germany.

Clinical Pharmacokinetics
|December 1, 1993
PubMed
Summary

Lamotrigine, a novel antiepileptic drug, is well-absorbed and exhibits linear pharmacokinetics. Its half-life is influenced by other antiepileptic drugs, but it generally shows a low incidence of reversible adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

Pharmacopsychiatry·2011
Same author

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Pharmacopsychiatry·2011
Same author

[Therapeutic drug monitoring in epileptology and psychiatry].

Der Nervenarzt·2007
Same author

Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs.

The Journal of small animal practice·2007
Same author

Language lateralization by Wada test and fMRI in 100 patients with epilepsy.

Neurology·2003
Same author

[Sunscreens. Protection against skin cancers and photoaging].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2003

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Pharmacy

Background:

  • Lamotrigine is a novel antiepileptic agent.
  • It is chemically distinct from existing antiepileptic drugs.
  • Understanding its pharmacokinetic and pharmacodynamic properties is crucial for effective use.

Purpose of the Study:

  • To characterize the pharmacokinetic profile of lamotrigine.
  • To investigate the influence of comedications on lamotrigine's half-life.
  • To assess the safety and tolerability of lamotrigine.

Main Methods:

  • High-performance liquid chromatography and immunoassays were used for drug estimation.
  • Pharmacokinetic parameters including absorption, bioavailability, protein binding, and elimination were determined.
  • Interactions with other antiepileptic drugs were evaluated.

Main Results:

  • Lamotrigine is rapidly absorbed with 98% oral bioavailability and dose-linear pharmacokinetics.
  • Mean half-life ranges from 22.8 to 37.4 hours, reduced by enzyme-inducers and increased by valproic acid.
  • Adverse effects are generally low in incidence and reversible.

Conclusions:

  • Lamotrigine demonstrates favorable pharmacokinetic properties and a good safety profile.
  • Dosage adjustments are necessary when co-administered with enzyme-inducing or inhibiting antiepileptic drugs.
  • Further research is needed to establish therapeutic drug monitoring guidelines.

Related Experiment Videos